

DEEP LEARNING PREDICTION OF ADVERSE DRUG REACTION ANALYSIS USING ARTIFICIAL NEURAL NETWORK MODEL

Mrs. K.E. Eswari, M.C.A., M.Phil., M.E., SET.,¹, R. Sarathkumar²,

¹Associate Professor, Department of Computer Applications, Nandha Engineering College (Autonomous), Erode, Tamilnadu, India.

²Final MCA, Department of Computer Applications, Nandha Engineering College (Autonomous), Erode, Tamilnadu, India.

Email: ¹eswarisaravanan2001@gmail.com, ²rajasarath28@gmail.com

Abstract.

In medical domain, Adverse Drug Reaction (ADR) analysis is a crucial process for doctors and medical scientists. Adverse drug reaction measures the injury occurred due to usage of a drug. The growing concern to the ADRs has stimulated the progress of statistical, data mining methods to find the Adverse Drug Reactions. This project proposed a hybrid model of data mining and machine learning to classify different Adverse Reactions and foretell the outcome intensity. It used the Proportionality Reporting Ratio (PRR) along with Chi-Square test equations to find out the different relationships between drug and symptoms called the drug-ADR association. In addition, support vector machine method is applied to classify the data set records into either normal or adverse drug. Moreover, our project aims in finding the percent of adversity of the drug reaction. Based on the number of occurrences, where a specific drug P, causes a specific Adverse Reaction, R, the various terms are measured for PRR and Chi Square. In addition KNN and SVM classification is made on drug records to classify them based on data set columns. Neural network based classification is the proposed system to classify drug reaction based on data set columns.

Keywords: Adverse Drug Reaction, Proportionality Reporting Ratio, Chi Square, Neural Network.

I. INTRODUCTION

This project used the Proportionality Reporting Ratio (PRR) along with the precision point estimator test called the Chi-Square test to find out the different relationships between drug and symptoms called the drug-ADR association. This output is used as an input to machine learning algorithms such as Random Forest and Support Vector Machine (SVM) to predict the intensity of the

outcomes of ADR. The aforementioned challenges motivated a series of works that apply data mining and machine learning approaches to come up with various solutions using different datasets to suit according to the researcher's needs. Google recently worked on a Twitter dataset to detect ADEs from posts on Twitter using a merged form of Artificial Neural Network (ANN).

ANN uses a binary classifier to represent outcome result. Another researcher proposed the Predictive Pharmacosafety Networks (PPNs) for detecting unknown ADEs. The existing drug safety information is used from a well-known data set of drug safety in 2005 to train a logistic regression model to detect unknown ADEs. In 2012, a research used the 'THIN' database to create a model using the feature matrix and feature selection to identify ADRs for a specific drug called "Pravastatin".

In the world of medical science and drugs, Adverse Drug Reaction (ADR) has always been an important field of research. Adverse drug reaction means the injury from the use of a drug. These injuries can extend from minor injuries like skin rash to major life-threatening reactions.

Confusion occurs mostly between ADR and Side Effect where ADR is the reaction caused by the drug used at normal doses for particular symptoms. Point to be noted: a wrongful overdose of drugs is not considered as an ADR case.

Every Year more than 200 thousand deaths are reported because of ADRs. Though ADR can be identified very easily after the occurrence, predicting ADR has always been a huge challenge for researchers. Worldwide, around 4.9% of hospital admissions are the result of ADRs and this number is as high as 41.3% in some areas. In Sweden, ADRs are the seventh most common cause of death. Even though drugs are thoroughly tested clinically before they are

released on the market, many unknown side effects are discovered after they have been used over time by various patients. Moreover, as ADR varies from person to person, predicting ADR can sometimes be as hard as impossible even for doctors.

Nowadays almost 73% of the people around the world take different medications. Among these, almost 29% of these medicines have different kinds of adverse drug reactions. FDA statistics show that almost 7000 of these ADRs have caused death in recent years.

This project tried to predict the ADR and its intensity so that necessary precautions can be taken before prescribing any kinds of medications. In recent years, a huge amount of Electronic Medical Records (EMR) is available on several platforms. As a result, various methods of data science can be implemented for the detection of ADR.

Various methods of machine learning and data mining have already been implemented to predict the possible ADR from a specific drug. However, this project proposed a hybrid model of machine learning and data mining to predict the ADR and its severity. We contributed mostly on the machine learning part where we took the detected ADR from the already existing, statistical data mining techniques and used it to find the severity of the reaction on various unique patients.

II. LITERATURE REVIEW

Adverse Medicine events beget substantial morbidity and mortality, yet they remain uncredited and misknew. The language to describe crimes and patient detriment associated with specific causes important confusion. This composition uses the case study of a case with multiple adverse medicine events to clarify crucial terms, similar as adverse event, adverse medicine response, adverse medicine event, drug error, and side effect. The case discussion illustrates clinical approaches to assaying the unproductive connection between a suspect medicine and an adverse event. Exemplifications and explanation for meaningful attestation of adverse medicine events are handed, along with a figure of the types of events that should be reported to non-supervisory agencies.

Since the early 1990s, adverse medicine events have entered significant attention from experimenters in quality and patient safety (11). Nationally honored quality experts have linked adverse medicine events as a top safety precedence (12) because these events are the most common type of iatrogenic injury (13). Studies have indicated that adverse medicine events do nearly daily in medium-sized hospitals and inpatient panels (14 – 16).

Still, despite the high morbidity and mortality, croakers frequently don't fete or meetly treat cases of medicine-related detriment (17, 18). The authors believed that shy recognition and treatment of medicine-related detriment are, in part, a result of what has been called a Palace of Babel of language (11). Terms firstly developed in the narrow environment of medicine goods in a clinical and non-supervisory setting are now being applied in the broader environment of quality enhancement in health care delivery systems (19).

As might be anticipated, the expanding part of these terms has been coupled with their use in antithetical ways, indeed within the same discipline (20). In this paper, they used the case of an factual case as a frame to explain the recognition, treatment, attestation, and reporting of medicine-related detriment.

ADVERSE EVENTS VERSUS ADVERSE Medicine Responses Mr. J. was a 70- time-old man with nephrotic pattern, pneumoconiosis, and a history of gout and myocardial infarction. He presented to the sanitarium with adding bilateral leg edema and pain, for which he'd been taking untoward ibuprofen, 400 mg three times a day for 3 days and once a day for the antedating 3 weeks. His other inpatient specifics were simvastatin, 40 mg at bedtime; aspirin, 81 mg formerly daily; and metoprolol, 50 mg doubly daily. In the exigency department, his serum creatinine position was 680 spook/ L (7.7 mg/ dL), much advanced than the birth of 290 spook/ L (3.3 mg/ dL) 11 months before. He was admitted to the sanitarium. The case endured an adverse event while using ibuprofen.

Is this event a side effect, an adverse medicine response, a drug error, or an exacerbation of his underpinning renal and cardiac complaint? Terms that originally arose from the field of pharmacovigilance, similar as adverse event and adverse medicine response, can help croakers relate the edema and renal failure to ibuprofen. Pharmacovigilance is the study of medicine-related injuries for the purpose of making warning or pullout recommendations for pharmaceutical products. The International Conference on Harmonisation of Technical Conditions for Registration of Medicinals for Human Use, of which the U.S. Food and Drug Administration (FDA) and the World Health Organization are members, defines an adverse event as “any untoward medical circumstance that may present during treatment with a pharmaceutical product but which doesn't inescapably have a unproductive relationship with this treatment”.

In this paper (2) the authors studied the problem of detecting rulings describing adverse medicine responses (ADRs) and frame the problem as double bracket. They delved different neural network (NN) infrastructures for ADR bracket. In particular, we propose two new neural network models, Artificial Intermittent Neural Network (CRNN) by concatenating Artificial neural networks with intermittent neural networks, and Artificial Neural Network with Attention ANNA by adding also the attention weights into ANN. They estimated colorful NN infrastructures on a Twitter dataset containing informal language and an Adverse Drug Goods (ADE) dataset constructed by slice from MEDLINE case reports.

Experimental results show that all the NN infrastructures outperform the traditional maximum entropy classifiers trained from n-grams with different weighting strategies vastly on both datasets. On the Twitter dataset, all the NN infrastructures perform also. However, in the ADE dataset, neural network does better than other more complex ANN variants. Nonetheless, ANNA allows the

visualization of attention weights of words when making bracket opinions and hence is more applicable for the birth of word subsequences describing ADRs. Adverse Medicine Responses (ADRs) are potentially veritably dangerous to cases and are amongst the top causes of morbidity and mortality. Numerous ADRs are hard to discover as they be to certain groups of people in certain conditions and they may take a long time to expose. Healthcare providers conduct clinical trials to discover ADRs before dealing the products but typically are limited in figures.

Therefore, post-market medicine safety monitoring is needed to help discover ADRs after the medicines are vended on the request. In the United States, Robotic Reporting Systems (SRSs) is the sanctioned channel supported by the Food and Drug Administration. Still these system are generally under-reported and numerous ADRs aren't recorded in the systems.

Lately unshaped data similar as medical reports or social network data have been used to descry content that contains ADRs. Case reports published in the scientific biomedical literature are abundant and generated fleetly. Social networks are another source of spare data with unshaped format. If the individual tweet or status in Facebook contains ADRs, it may not be clinically useful, and so a large volume of these data can expose unknown or serious consequences. Common approaches to descry content with ADRs used Support Vector Machines

(SVMs), Random Forest, Maximum Entropy classifiers with heavily hand- finagled features. These features typically include n-grams with different weighting schemes.

When used with unigrams, these approaches suffer from the fact that their models don't take in account the commerce between terms and their orders. This problem can incompletely be answered by using bi-grams or trigrams. Still this leads to the number of features exploding, and the models are therefore fluently overfitted. Meanwhile neural networks with pre-trained word representations have had some successes in other textbook bracket tasks.

Word representations that are generally pre-trained with unlabelled data are matrices that can be used to project words into a thick low-dimensional space (generally from 50 to 300 confines). These neural networks of ten contain Artificial pollutants or intermittent connections that cipher weighted totalities of words and their surrounds. The authors in this paper, trained a) word embeddings and b) use them as parameters to different neural network infrastructures for classifying documents to whether they contain ADR content or not.

They concluded that this paper has explored different neural network (NN) infrastructures for ADR bracket. In particular, they have proposed two new neural network models, a) Artificial Intermittent Neural Network (CRNN) and b) Artificial Neural Network with Attention (ANNA). Experimental results verify that all the NN infrastructures outperform traditional Maximum Entropy classifiers trained from "n-grams" with varying weighting strategies vastly on both Twitter and ADE datasets.

Among NN infrastructures, no significant differences were observed on the Twitter dataset. But ANN seems to do better when compared with other more complex ANN variants on ADE dataset. Nonetheless, ANNA allows the visualization of attention weights of words when making bracket opinions and hence is more applicable for the birth of word subsequences describing ADRs.

The authors of this research [3] noted that adverse drug reactions (ADR) are a major public health concern. They suggested a novel approach to detect ADRs using a feature matrix and feature selection in this work. The tests are conducted on the medication Pioglitazone.

When compared to other automated systems, major negative effects for the drug are discovered, and better

performance is attained. The observed ADRs were discovered using an automated method, and more research is required.

Adverse drug reactions (ADR) are a major public health concern. ADRs are one of the most common reasons why medications are withdrawn from the market. The spontaneous reporting system (SRS) and prescription event monitoring are now the two main strategies for detecting ADRs (PEM).

In pharmacovigilance, a signal is defined as "any published information on a putative causative association between an adverse event and a medicine, the relationship being unknown or incompletely documented previously," according to the World Health Organization (WHO). Many machine learning methods, such as Bayesian confidence propagation neural network (BCPNN), decision support method, genetic algorithm, knowledge based approach, and others, are employed to detect ADRs in the spontaneous reporting system.

One shortcoming is the reporting method for submitting ADR reports, which suffers from significant underreporting and is unable to adequately evaluate the risk. Another problem is that ADRs are difficult to detect in databases with a small number of occurrences of each drug-event connection. We present a feature selection strategy for detecting ADRs in The Health Improvement Network (THIN) database in this research.

By connecting patients' prescriptions and accompanying medical occurrences, the first feature matrix is constructed, which reflects medical events for patients before and after taking medications. Then, using feature selection methods, significant characteristics are picked by comparing the feature matrix before and after patients take medications.

Finally, based on comparable traits, substantial ADRs can be discovered from thousands of medical occurrences. The drug Pioglitazone is the subject of research. A good result is obtained. The first feature matrix is taken from the THIN database, which summarises the medical events that patients experience before or after taking medications, in order to detect drug ADRs.

Then, using the Student's t-test feature selection approach, significant features are selected from a feature matrix containing thousands of medical occurrences. The authors concluded that using a feature matrix and feature selection, they provided a unique method for successfully detecting ADRs.

The THIN database is used to generate a feature matrix that defines medical occurrences before and after individuals take medications.

The Student's t-test feature selection approach is used to identify relevant features in thousands of medical events. Significant ADRs are identified, which connect to significant traits. The drug Pioglitazone is the subject of research. In comparison to existing automated methods, the proposed method performs well

III. PROPOSED METHODOLOGY

In existing system, to find an association between the drug and the symptoms accountable for the prescribed drug, data mining association techniques such as Chi-Square and Proportionality Reporting Ratio (PRR) are used which give numerical values for the model. If the values exceed a certain threshold, that specific symptom is identified as an ADR for a certain drug. The general conditions for running the PRR are as mentioned below:

- Value A refers to the number of occurrences, where a specific drug P, causes a specific Adverse Reaction, R.
- Value B refers to the number of occurrences, where specific drug P causes any other Adverse Reactions but R.
- Value C refers to the number of occurrences, where the Adverse Reaction R is caused by any other drug but P.
- Value D refers to the number of occurrences, where any other Adverse Reactions but R is caused by any other drugs but P

$$PRR = (A / (A+B)) / (C / (C+D))$$

$$\text{Chi Square } X^2 = \frac{(AD-BC)^2 + (A+B+C+D)}{[(A+B)(B+C)(C+D)(A+D)]}$$

The threshold value for Chi-Square and PRR:

- $PRR > 2$
- $\text{Chi-Square} > 4$.

The drug reactions with values greater than the threshold are matched with already given symptoms by the

user. If there is any cross match, then that is considered as a potential ADR. Drawbacks are:

- Decides only if the drug is fully adverse or not.
- Threshold value is not pre-decided.
- The existing system surely does not give precise results.
- Based on the PRR values, doctors need to decide them manually for ADR or not.
- KNN and SVM classification is not made on drug records to classify them.

In proposed system, all the existing approaches are carried out. In addition, SVM classification is carried out in which 80% of the data are given as training data. The 20% of the data are taken as test data. KNN and SVM classification is also made to classify the drugs based on dataset columns.

The probability value attribute of the SVM model is set to true and so the test data record yields a numeric value between zero and one which indicates the level of adversity of the drug for that record values. So, unlike existing system which gives either ADR or not, here the percentage of adversity could be found out. Advantages are:

- Decides the level of drug adversity.
- Threshold value is not required.
- The proposed system gives precise results. Based on the SVM values, ADR level could be found out.
- KNN and SVM classification is made on drug records to classify them based on data set columns.

IV. FINDINGS

To achieve Adverse Drug Reaction analysis results, the dataset itself should be improved in so many ways.

A patient's blood group, diabetes information, pregnancy condition (female patients) can be very important factors in determining specific ADRs or to predict the outcome of an ADR. This information is missing from our dataset.

So, if a new dataset can be formed comprising of the valuable information and our above-mentioned concepts are applied to the dataset, a much better result can be achieved.

Secondly, since ADRs are person specific mostly and can vary from patient to patient, a groundbreaking result can be achieved if the genetic diagnosis information is available for all the patients and can be used in determining the ADRs.

Moreover, if information about the drugs is available on a molecular level, they can be aided with the person's genetic information to create a more stable system for the prediction of Adverse Drug Reaction and their intensity.

If the new system, applies KNN and SVM prediction model, then the prediction will be adoptable for future new drug records.




FIG 4.1 PROPORTIONALITY REPORTING RATIO VALUES




FIG 4.2 CHI SQUARE VALUES


```

73 #row(df2_test)
74 summary(pr)
75 cat("Predicted values for Test Records\n")
76 cat(".....\n")
77
78 print(pr)
79 df2_testnew <- df2_test
80 df2_testnew$colnames(df2_testnew[binarycolumnindex]) <-pr
81 #df2_testnew[,df2_testnew[,1]] <-pr
82 print(df2_testnew)
83 cat(".....\n")
84 #df2_testnew[,32:36]
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

```

FIG 4.3 KNN CLASSIFICATION BASED PREDICTED VALUES

```

# Create confusion matrix
> tab <- table(pr, df2_test$category)
# Prints function divided the correct predictions by total number of predictions that tell us how accurate the model is.
> accuracy <- function(x){sum(diag(x))/sum(rows(x))} * 100
> cat("Accuracy of this knn model is:\n")
[1] 1.1

```

FIG 4.4. ACCURACY OF THE KNN MODEL

V. CONCLUSION

The project has explored various concepts of data mining and machine learning and attempted to come up with a hybrid model that will help doctors and pharmacists to perform a safe drug evaluation on a combination of drugs before they prescribe medicine to the patients. The Proportionality Reporting Ratio (PRR) and Chi-Square tests are used as the data mining technique to help evaluate the correct combination of safe drugs to be prescribed to the patient and also, it went further ahead with the proposed machine learning concepts to help doctors and pharmacists to be well aware of the outcome of an Adverse Event if it were to occur from a combination of drugs. A drug is considered safe until an adverse reaction is reported for that drug. However, in the field of medicine, there is always scope for uncertainty since each drug can react differently to different specific patients. This system can be used as a complimentary tool with the doctor's knowledge

and can help aid them in performing a safe drug diagnosis and prescribe the correct combination of medicine to the patient. In addition, this project classifies the drug data set records using KNN and neural network to predict the model for future test record data sets. It will be helpful in analyzing the drug in the current data set and so as to predict the future upcoming dataset. In future, logistic regression can be applied to further classify the data.

REFERENCES

- [1] J. Nebeker, P. Barach and M. Samore, "Clarifying Adverse Drug Events: A Clinician's Guide to Terminology, Documentation, and Reporting", *Annals of Internal Medicine*, vol. 140, no. 10, p. 795, 2004.
- [2] T. Huynh, Y. He, A. Willis and S. R'uger, "Adverse Drug Reaction Classification With Deep Neural Networks", in *Proceedings of COLING 2016, the 26th International Conference on Computational Linguistics: Technical Papers*, Osaka, Japan, 2016, pp. 877-887.
- [3] Y. Liu and U. Aickelin, "Detect adverse drug reactions for drug Pioglitazone", 2012 IEEE 11th International Conference on Signal Processing, 2012.
- [4] L. Duan, M. Khoshneshin, W. Street and M. Liu, "Adverse Drug Effect Detection", *IEEE Journal of Biomedical and Health Informatics*, vol. 17, no. 2, pp. 305-311, 2013.
- [5] A. Tripathy, N. Joshi, H. Kale, M. Durando and L. Carvalho, "Detection of adverse drug events through data mining techniques", in *2015 International Conference on Technologies for Sustainable Development (ICTSD)*, Mumbai, India, 2015, pp. 01-06.
- [6] Ross SD. Drug-related adverse events: a readers' guide to assessing literature reviews and meta-analyses. *Arch Intern Med*. 2001;161:1041-6. [PMID:11322836]
- [7] Shojania KG, Duncan BW, McDonald KM, Wachter RM. Safe but sound: patient safety meets evidence-based medicine [Editorial]. *JAMA*. 2002;288:50813. [PMID: 12132985]
- [8] Kohn LT, Corrigan JM, Donaldson MS. *To Err Is Human: Building a Safer Health System*. Washington, DC: National Academy Pr; 1999.
- [9] Bates DW, Cullen DJ, Laird N, Petersen LA, Small SD, Servi D, et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. *JAMA*. 1995;274:29-34. [PMID: 7791255]
- [10] Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, et al. Adverse drug events in ambulatory care. *N Engl J Med*. 2003;348:1556-64. [PMID: 12700376]
- [11] Fattinger K, Roos M, Vergeres P, Holenstein C, Kind B, Masche U, et al. Epidemiology of drug exposure and

adverse drug reactions in two swiss departments of internal medicine. Br J Clin Pharmacol. 2000;49:158-67. [PMID: 10671911]

[12] Beatrice A. Golomb, John J. McGraw, Marcella A. Evans and Joel E. Dimsdale. Physician Response to Patient Reports of Adverse Drug Effects Implications For Patient-Targeted Adverse Effect Surveillance. Drug Safety 2007; 30 (8): 669-675. 0114-5916/07/0008-0669/\$44.95/0. © 2007 Adis Data Information BV.